Hormonal
Obesity pathogenesis is driven by a complex network of 802 core genetic risk genes that function through integrated neurological (appetite regulation, synaptic signaling) and metabolic (lipid/glucose homeostasis) pathways.
Obesity is not just a lifestyle choice; it is heavily influenced by your genetics. If you have a family history of obesity, your body may regulate appetite and metabolism differently. This doesn't mean you can't lose weight, but it means you may need more targeted strategies, such as medical interventions that address specific hormonal pathways (like GLP-1 or MC4R agonists), rather than relying on standard diet advice alone.
Our protein–protein interaction (PPI) network analysis revealed that these genes form a tightly connected functional network primarily involved in neurological and metabolic regulatory processes.
Why this rating
The study is a bioinformatics and transcriptomic analysis using public datasets, lacking direct clinical intervention or causal human validation.
Source
A Complex Network of Obesity‐Risk Genes Revealed by Systematic Bioinformatics and Single‐Cell Transcriptomic Analyses
Y. Liu et al. · Journal of Obesity · 2025
DOI 10.1155/jobe/7821115
More from this paper
- Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.Good
- Obesity-risk genes are highly expressed in specific cell types: hypothalamic neurons (regulating appetite), pancreatic beta-cells (regulating insulin), adipocytes (lipid homeostasis), and hepatocytes (lipid metabolism).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →